摘要
目的分析中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR)预测程序性细胞死亡蛋白1(PD-1)/程序性细胞死亡蛋白配体1(PD-L1)抑制剂治疗晚期肿瘤患者效果及预后的价值。方法选取我院收治的140例晚期肿瘤患者为研究对象。患者均给予PD-1/PD-L1抑制剂治疗,根据疗效将其分为有效组和无效组。比较两组的NLR、PLR,分析NLR、PLR与患者疗效的相关性,探究影响PD-1/PD-L1抑制剂治疗晚期肿瘤患者预后的因素。结果140例晚期肿瘤患者中,治疗有效117例(83.57%),治疗无效23例(16.43%)。无效组的NLR0、PLR0、NLR2、PLR2高于有效组(P<0.05)。Spearman相关性分析结果显示,NLR0、PLR0、NLR2、PLR2与PD-1/PD-L1抑制剂治疗晚期肿瘤患者的疗效呈负相关(P<0.05)。单因素分析结果显示,不同治疗2个周期疗效、NLR0、PLR0、NLR2、PLR2 PD-1/PD-L1抑制剂治疗晚期肿瘤患者的生存期比较,差异具有统计学意义(P<0.05)。多因素分析结果显示,治疗2个周期疗效、NLR0、PLR0、NLR2、PLR2是PD-1/PD-L1抑制剂治疗晚期肿瘤患者预后的独立预测因素(P<0.05)。结论NLR和PLR与PD-1/PD-L1抑制剂治疗晚期肿瘤患者效果及预后密切相关。
Objective To analyze the value of neutrophil-to-lymphocyte ratio(NLR)and platelet to lymphocyte ratio(PLR)in predicting the efficacy and prognosis of programmed cell death protein 1(PD-1)/programmed cell death-ligand 1(PD-L1)inhibitors in patients with advanced tumors.Methods A total of 140 patients with advanced tumors admitted in our hospital were selected as the research objects.All patients were treated with PD-1/PD-L1 inhibitors,and were divided into effective group and ineffective group according to the curative effect.The NLR and PLR of the two groups were compared,the correlation between NLR and PLR and the efficacy of patients were analyzed,and the factors affecting the prognosis of patients with advanced tumors treated with PD-1/PD-L1 inhibitors were explored.Results Among 140 patients with advanced tumors,117 cases(83.57%)were effective and 23 cases(16.43%)were ineffective.The NLR0,PLR0,NLR2 and PLR2 in the ineffective group were higher than those in the effective group(P<0.05).Spearman correlation analysis results showed that NLR0,PLR0,NLR2 and PLR2 were negatively correlated with the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced tumors(P<0.05).The results of univariate analysis showed that there were statistically significant differences in the survival time of patients with advanced tumors treated with PD-1/PD-L1 inhibitors between different effect of 2 cycles of treatment,NLR0,PLR0,NLR2 and PLR2(P<0.05).Multivariate analysis results showed that effect of 2 cycles of treatment,NLR0,PLR0,NLR2 and PLR2 were independent predictors of prognosis in patients with advanced tumors treated with PD-1/PD-L1 inhibitors(P<0.05).Conclusion NLR and PLR are closely related to the efficacy and prognosis of PD-1/PD-L1 inhibitors in the treatment of patients with advanced tumors.
作者
赵丽丽
ZHAO Lili(Oncology Department,Affiliated Huishan Hospital of Xinglin College,Nantong University/Wuxi Huishan District People's Hospital,Wuxi 214000,China)
出处
《临床医学研究与实践》
2025年第23期38-41,共4页
Clinical Research and Practice
